Search
tacrolimus topical (Protopic)
Indications:
-> topical treatment of atopic dermatitis
-> reserve for patients who cannot use or do not respond to topical steroids
Dosage: 0.1% & 0.03%
Pharmacokinetics:
-> minimal systemic absorption, especially with intact skin
Adverse effects:
1) photosensitivity
2) increased risk of skin cancer [2]
Mechanism of action:
-> suppresses T-cells that cause skin inflammation
Interactions
drug adverse effects of immunosuppressive agents
monitor with immunosuppressive agents
General
tacrolimus; FK506; fujimycin (Prograf, Advagraf, Envarsus XR)
topical immunomodulator (TIM)
Database Correlations
PUBCHEM cid=64779
References
- Prescriber's Letter 8(2):9 2001
- Prescriber's Letter 12(4): 2005
FDA Public Health Advisory Elidel (pimecrolimus) Cream and
Protopic (tacrolimus) Ointment
Detail-Document#: 210407
(subscription needed) http://www.prescribersletter.com
http://www.fda.gov/bbs/topics/ANSWERS/2005/ANS01343/htm
- Journal Watch 25(9):75, 2005
Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC.
Efficacy and tolerability of topical pimecrolimus and tacrolimus
in the treatment of atopic dermatitis: meta-analysis of
randomised controlled trials.
BMJ. 2005 Mar 5;330(7490):516. Epub 2005 Feb 24. Review.
PMID: 15731121
http://bmj.bmjjournals.com/cgi/content/full/330/7490/503